MX2022007595A - Triterpenoides sinteticos con sustituyentes a base de nitrogeno en c-17 y metodos de uso de los mismos. - Google Patents
Triterpenoides sinteticos con sustituyentes a base de nitrogeno en c-17 y metodos de uso de los mismos.Info
- Publication number
- MX2022007595A MX2022007595A MX2022007595A MX2022007595A MX2022007595A MX 2022007595 A MX2022007595 A MX 2022007595A MX 2022007595 A MX2022007595 A MX 2022007595A MX 2022007595 A MX2022007595 A MX 2022007595A MX 2022007595 A MX2022007595 A MX 2022007595A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- nitrogen
- aspects
- based substituents
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
- C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Ophthalmology & Optometry (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Transplantation (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
En algunos aspectos, la presente descripción proporciona compuestos de la fórmula: (ver Fórmula) (I) y (ver Fórmula) (II), en donde las variables se definen en la presente. También se proporcionan composiciones farmacéuticas de los mismos. En algunos aspectos, los compuestos y composiciones proporcionados en la presente se pueden usar como moduladores antioxidantes de la inflamación. En algunos aspectos, la presente descripción proporciona métodos, en donde los compuestos y composiciones descritos en la presente se usan para el tratamiento de enfermedades y trastornos asociados con la inflamación y cáncer.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962950919P | 2019-12-19 | 2019-12-19 | |
| US201962950927P | 2019-12-19 | 2019-12-19 | |
| US202063198310P | 2020-10-09 | 2020-10-09 | |
| PCT/US2020/066073 WO2021127480A1 (en) | 2019-12-19 | 2020-12-18 | Synthetic triterpenoids with nitrogen-based substituents at c-17 and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022007595A true MX2022007595A (es) | 2022-07-19 |
Family
ID=74554207
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022007595A MX2022007595A (es) | 2019-12-19 | 2020-12-18 | Triterpenoides sinteticos con sustituyentes a base de nitrogeno en c-17 y metodos de uso de los mismos. |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20230111914A1 (es) |
| EP (1) | EP4077347A1 (es) |
| JP (1) | JP2023507402A (es) |
| KR (1) | KR20220116209A (es) |
| CN (1) | CN115087660A (es) |
| AU (1) | AU2020405181A1 (es) |
| BR (1) | BR112022011919A2 (es) |
| CA (1) | CA3159778A1 (es) |
| CL (1) | CL2022001661A1 (es) |
| CO (1) | CO2022010070A2 (es) |
| CR (1) | CR20220345A (es) |
| DO (1) | DOP2022000127A (es) |
| EC (1) | ECSP22055210A (es) |
| IL (1) | IL293876A (es) |
| MX (1) | MX2022007595A (es) |
| PE (1) | PE20221662A1 (es) |
| TW (1) | TW202135828A (es) |
| WO (1) | WO2021127480A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2021397631A1 (en) * | 2020-12-11 | 2023-07-20 | Reata Pharmaceuticals Holdings, LLC | Synthetic triterpenoids for use in therapy |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2703274T3 (es) * | 2008-04-18 | 2019-03-07 | Reata Pharmaceuticals Inc | Moduladores de la inflamación antioxidantes: derivados del ácido oleanólico con modificaciones amino y otras en C-17 |
| KR101782020B1 (ko) * | 2008-04-18 | 2017-09-26 | 리타 파마슈티컬스 잉크. | 산화방지성 염증 조절제 ｃ-17 일치된 올레아놀산 유도체 |
| TWI442925B (zh) * | 2008-04-18 | 2014-07-01 | Reata Pharmaceuticals Inc | 抗氧化性發炎調節劑：ｃ－環飽和之齊墩果酸衍生物 |
| UY39092A (es) * | 2013-04-24 | 2021-03-26 | Abbvie Inc | Derivados de 2,2-difluoropropanamida y metil bardoxolona, formas polimórficas y métodos de uso |
| US20220017566A1 (en) * | 2018-09-28 | 2022-01-20 | Sichuan Haisco Pharmaceutical Co., Ltd. | Terpinoid derivatives and uses thereof |
-
2020
- 2020-12-18 KR KR1020227023129A patent/KR20220116209A/ko active Search and Examination
- 2020-12-18 CN CN202080096545.0A patent/CN115087660A/zh active Pending
- 2020-12-18 MX MX2022007595A patent/MX2022007595A/es unknown
- 2020-12-18 CA CA3159778A patent/CA3159778A1/en active Pending
- 2020-12-18 IL IL293876A patent/IL293876A/en unknown
- 2020-12-18 BR BR112022011919A patent/BR112022011919A2/pt unknown
- 2020-12-18 PE PE2022001140A patent/PE20221662A1/es unknown
- 2020-12-18 US US17/757,701 patent/US20230111914A1/en active Pending
- 2020-12-18 JP JP2022537305A patent/JP2023507402A/ja active Pending
- 2020-12-18 WO PCT/US2020/066073 patent/WO2021127480A1/en active Application Filing
- 2020-12-18 EP EP20851264.0A patent/EP4077347A1/en active Pending
- 2020-12-18 AU AU2020405181A patent/AU2020405181A1/en active Pending
- 2020-12-18 CR CR20220345A patent/CR20220345A/es unknown
- 2020-12-18 TW TW109145170A patent/TW202135828A/zh unknown
-
2022
- 2022-06-17 CL CL2022001661A patent/CL2022001661A1/es unknown
- 2022-06-17 DO DO2022000127A patent/DOP2022000127A/es unknown
- 2022-07-15 EC ECSENADI202255210A patent/ECSP22055210A/es unknown
- 2022-07-18 CO CONC2022/0010070A patent/CO2022010070A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW202135828A (zh) | 2021-10-01 |
| JP2023507402A (ja) | 2023-02-22 |
| CR20220345A (es) | 2023-01-12 |
| AU2020405181A1 (en) | 2022-07-14 |
| PE20221662A1 (es) | 2022-10-26 |
| CN115087660A (zh) | 2022-09-20 |
| EP4077347A1 (en) | 2022-10-26 |
| DOP2022000127A (es) | 2022-09-15 |
| US20230111914A1 (en) | 2023-04-13 |
| KR20220116209A (ko) | 2022-08-22 |
| ECSP22055210A (es) | 2022-08-31 |
| CL2022001661A1 (es) | 2023-01-27 |
| IL293876A (en) | 2022-08-01 |
| WO2021127480A1 (en) | 2021-06-24 |
| CA3159778A1 (en) | 2021-06-24 |
| CO2022010070A2 (es) | 2022-08-09 |
| BR112022011919A2 (pt) | 2022-09-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR20220363A (es) | Compuestos tricíclicos sustituidos | |
| MY196582A (en) | PD-1/PD-L1 Inhibitors | |
| PH12019502245A1 (en) | Compounds that inhibit mcl-1 protein | |
| WO2019222112A8 (en) | Mcl-1 inhibitors | |
| WO2018049152A8 (en) | Pyrazolopyrimidine derivatives as hpk1 modulators and uses thereof for the treatment of cancer | |
| CR20220312A (es) | Compuestos tricíclicos sustituidos | |
| CR20200614A (es) | Compuestos heterocíclicos como inmunomoduladores | |
| CR20210335A (es) | Compuestos de 2-formil-3-hidroxifeniloximetilo capaces de modular la hemoglobina | |
| MX2020013853A (es) | Compuestos innovadores. | |
| MX2018005019A (es) | Derivado benzofurano, su metodo de preparacion, y sus usos en medicinas. | |
| JO3474B1 (ar) | مشتقات تيتراهيدرونافثالين التي تثبط بروتين mcl-1 | |
| MX370586B (es) | Imidazolil enonas triciclicas como moduladores de inflamacion antioxidantes. | |
| MX2019003397A (es) | Metodos para tratar trastornos mitocondriales y metabolicos. | |
| PH12020551043A1 (en) | Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues | |
| CR20190433A (es) | Compuestos de pirimidinil-pyridiloxi-naftil y métodos para tratar enfermedades y trastornos relacionados con ire1 | |
| WO2019035863A8 (en) | PYRUVATE KINASE ACTIVATORS FOR USE IN THE TREATMENT OF HEMATOLOGICAL DISORDERS | |
| CR20220215A (es) | Heteroaril bifenil amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1 | |
| ZA202201364B (en) | Deuterated compounds for use in the treatment of cancer | |
| MX2020012281A (es) | Composiciones que comprenden compuestos de bisfluoroalquil-1,4-ben zodiacepinona y metodos de uso de las mismas. | |
| WO2021100029A3 (en) | Prodrugs of fulvestrant | |
| MX2022000712A (es) | Moduladores de nlrp3. | |
| MX2022007595A (es) | Triterpenoides sinteticos con sustituyentes a base de nitrogeno en c-17 y metodos de uso de los mismos. | |
| ZA202106519B (en) | Caspase inhibitors and methods of use thereof | |
| WO2021041324A3 (en) | Compositions and methods for the treatment of pathological pain and itch | |
| WO2020097568A3 (en) | Oligosaccharide compositions and methods of use thereof |